drug
eribulin mesylate
Marketedupdated 3mo agoby Eisai Co Ltd
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 1all catalysts(0)
nothing on the calendar yet
Trials studying eribulin mesylate
- phase1Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery
- phase3Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
- phase3A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
- phase3JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
- phase2EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma
- EP1Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors
- phase2A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
- phase2A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 8, 2027
149 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Jul 8, 2027patentUS RE46965*PED330d
- Jan 8, 2027formulationUS RE46965149d
FDA exclusivities (2)
- Mar 13, 2026PEDPediatric (6mo bonus)
- Sep 13, 2025M-280Method (3y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 54m ago
Found something off?
comments(0)
5-min edit window · permanent after that